Publication | Closed Access

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

Interim AnalysisLymphoid NeoplasiaMedicineImmunologyPathologyImmune Checkpoint InhibitorCancer TreatmentAdult T-cell Leukemia-lymphomaImmunotherapyOncologyRadiation Oncology